Alkermes/$ALKS
1D1W1MYTD1Y5YMAX
Capital at risk
About Alkermes
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
- Ticker
- $ALKS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,050
- Headquarters
- Dublin, Ireland
- Website
- www.alkermes.com
Alkermes Metrics
BasicAdvanced
$7.7B
118.66
$0.39
0.29
-
Price and volume
Market cap
$7.7B
Beta
0.29
52-week high
$55.67
52-week low
$26.99
Average daily volume
1.4M
Financial strength
Current ratio
2.3
Quick ratio
1.681
Long term debt to equity
0.851
Total debt to equity
0.831
Interest coverage (TTM)
3.78%
Profitability
EBITDA (TTM)
284.932
Gross margin (TTM)
87.18%
Net profit margin (TTM)
3.97%
Operating margin (TTM)
13.39%
Effective tax rate (TTM)
32.06%
Revenue per employee (TTM)
$810,000
Management effectiveness
Return on assets (TTM)
4.20%
Return on equity (TTM)
3.85%
Valuation
Price to earnings (TTM)
118.665
Price to revenue (TTM)
4.584
Price to book
4.27
Price to tangible book (TTM)
-14.11
Price to free cash flow (TTM)
34.485
Free cash flow yield (TTM)
2.90%
Free cash flow per share (TTM)
1.336
Growth
Revenue change (TTM)
10.79%
Earnings per share change (TTM)
-81.32%
3-year revenue growth (CAGR)
4.48%
10-year revenue growth (CAGR)
9.59%
3-year earnings per share growth (CAGR)
-13.91%
10-year earnings per share growth (CAGR)
-14.35%
What the Analysts think about Alkermes
Analyst ratings (Buy, Hold, Sell) for Alkermes stock.
Analyst projections of the future price of Alkermes stock.
Bulls say / Bears say
Alkermes posted second-quarter 2026 revenue of $496.0 million, up from $390.7 million a year earlier, while proprietary product sales rose to $411.7 million from $307.2 million, indicating strong post-Avadel commercial momentum. (SEC filing)
LUMRYZ generated $96.6 million of second-quarter sales, and its REVITALYZ Phase 3 study met all primary and key secondary endpoints in idiopathic hypersomnia, supporting a potential future label expansion. (Alkermes)
Alixorexton advanced into Phase 3 studies for narcolepsy, has FDA Breakthrough Therapy designation for narcolepsy type 1, and received U.S. and European orphan-drug designations, strengthening Alkermes’ longer-term neuroscience growth opportunity. (Alkermes)
The Avadel acquisition added $1.525 billion of term loans, $75–$85 million of expected 2026 net interest expense, and sizable amortization and inventory step-up charges, increasing balance-sheet and integration risk. (Alkermes)
Second-quarter 2026 revenue benefited from approximately $7 million of LUMRYZ inventory-timing benefits and roughly $4 million each of favorable gross-to-net adjustments for ARISTADA and VIVITROL, raising concerns about the durability of reported growth. (SEC filing)
The key pipeline catalysts remain execution-dependent: alixorexton is still in pivotal testing, while LUMRYZ is not approved for idiopathic hypersomnia and cannot be marketed for that indication before March 1, 2028 even if approved earlier. (Alkermes)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Alkermes Financial Performance
Revenues and expenses
Alkermes Earnings Performance
Company profitability
Upcoming events
No upcoming events
Alkermes News
AllArticlesVideos
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
Business Wire1 week ago
The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Business Wire3 weeks ago
Alkermes Q2 Earnings Call Highlights
MarketBeat2 months ago
Funds containing Alkermes
AllUSDEURGBP
Fund name | Fund size | $ALKS weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.80% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.80% |
iShares Healthcare Innovation£DRDR | £1B | 0.80% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.52% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.52% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.